The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
Three companies that snagged approval late last week for generic versions of AstraZeneca’s asthma treatment Symbicort (budesonide + formoterol) - Toa Pharmaceuticals, Nipro, and Nihon Generic - codeveloped their copies to join the difficult-to-enter respiratory inhaler market, Jiho has learned.…
To read the full story
Related Article
- Nipro to Roll Out Symbicort Copy in June with Stable Supply System in Place
May 21, 2020
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
- 6 Drugs Face Generic Entries, 2 Firms to Roll Out Symbicort Copies: December Listing
December 12, 2019
- Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
- Toa Confident in Ensuring Stable Supply of Symbicort Generic with Expertise in Dry Powder Inhaler Manufacturing
March 8, 2019
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Japan Approves Symbicort Generics, Asthma Drug Stalwart Could Face Competition in June
February 15, 2019
BUSINESS
- Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
- Astellas, Yaskawa Electric to Form JV for Cell Therapy Production
March 10, 2025
- Sandoz’s Rituxan Biosimilar Adds Nephrotic Syndrome Use
March 10, 2025
- Japan Ethical Drug Sales Up 3.8% in January: Crecon
March 10, 2025
- Novartis Adjusts Entresto Shipments Ahead of Price Hike in Off-Year Revision
March 7, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…